si stat3 constructs Search Results


si apobec3b  (Obio Technology Corp Ltd)
86
Obio Technology Corp Ltd si apobec3b
<t>APOBEC3B</t> knockdown inhibits PD-L1, activates CD8 + T cells, and enhances ferroptosis. (A) Western blot analysis of PD-L1 expression in KYSE30 and KYSE30/DDP cells. (B) Western blot analysis of PD-L1 expression in KYSE30 cells treated with DDP for 0, 48, and 72 h, and untrested KYSE30/DDP cells. (C) Western blot analysis of PD-L1 expression in KYSE30 cells, and in KYSE30/DDP cells with or without APOBEC3B knockdown. (D) Immunofluorescence analysis of CD8 + T cell distribution in the tumor immune microenvironment of esophageal squamous cell carcinoma treated with si-NC, <t>si-APOBEC3B,</t> PD-L1 inhibitor, or a combination of si-APOBEC3B and PD-L1 inhibitor. (E) Expression of ROS, (F) LPO, and (G) MDA in esophageal squamous cell carcinoma tissues treated with si-NC, si-APOBEC3B, PD-L1 inhibitor, or a combination of si-APOBEC3B and PD-L1 inhibitor. (H) Western blot analysis of protein levels of the anti-ferroptosis gene FTL, pro-ferroptosis gene ACSL4, and glutathione metabolism-related genes GPX4 and GCLC in esophageal squamous cell carcinoma tissues after APOBEC3B knockdown.
Si Apobec3b, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/si+stat3+constructs/pmc12834936-141-5-6?v=Obio+Technology+Corp+Ltd
Average 86 stars, based on 1 article reviews
si apobec3b - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


APOBEC3B knockdown inhibits PD-L1, activates CD8 + T cells, and enhances ferroptosis. (A) Western blot analysis of PD-L1 expression in KYSE30 and KYSE30/DDP cells. (B) Western blot analysis of PD-L1 expression in KYSE30 cells treated with DDP for 0, 48, and 72 h, and untrested KYSE30/DDP cells. (C) Western blot analysis of PD-L1 expression in KYSE30 cells, and in KYSE30/DDP cells with or without APOBEC3B knockdown. (D) Immunofluorescence analysis of CD8 + T cell distribution in the tumor immune microenvironment of esophageal squamous cell carcinoma treated with si-NC, si-APOBEC3B, PD-L1 inhibitor, or a combination of si-APOBEC3B and PD-L1 inhibitor. (E) Expression of ROS, (F) LPO, and (G) MDA in esophageal squamous cell carcinoma tissues treated with si-NC, si-APOBEC3B, PD-L1 inhibitor, or a combination of si-APOBEC3B and PD-L1 inhibitor. (H) Western blot analysis of protein levels of the anti-ferroptosis gene FTL, pro-ferroptosis gene ACSL4, and glutathione metabolism-related genes GPX4 and GCLC in esophageal squamous cell carcinoma tissues after APOBEC3B knockdown.

Journal: Computational and Structural Biotechnology Journal

Article Title: Integrated metabolome and transcriptome analysis reveals ferroptosis involvement in cisplatin resistance of esophageal squamous cancer cell

doi: 10.1016/j.csbj.2026.01.003

Figure Lengend Snippet: APOBEC3B knockdown inhibits PD-L1, activates CD8 + T cells, and enhances ferroptosis. (A) Western blot analysis of PD-L1 expression in KYSE30 and KYSE30/DDP cells. (B) Western blot analysis of PD-L1 expression in KYSE30 cells treated with DDP for 0, 48, and 72 h, and untrested KYSE30/DDP cells. (C) Western blot analysis of PD-L1 expression in KYSE30 cells, and in KYSE30/DDP cells with or without APOBEC3B knockdown. (D) Immunofluorescence analysis of CD8 + T cell distribution in the tumor immune microenvironment of esophageal squamous cell carcinoma treated with si-NC, si-APOBEC3B, PD-L1 inhibitor, or a combination of si-APOBEC3B and PD-L1 inhibitor. (E) Expression of ROS, (F) LPO, and (G) MDA in esophageal squamous cell carcinoma tissues treated with si-NC, si-APOBEC3B, PD-L1 inhibitor, or a combination of si-APOBEC3B and PD-L1 inhibitor. (H) Western blot analysis of protein levels of the anti-ferroptosis gene FTL, pro-ferroptosis gene ACSL4, and glutathione metabolism-related genes GPX4 and GCLC in esophageal squamous cell carcinoma tissues after APOBEC3B knockdown.

Article Snippet: Lentivirus vectors incorporating si-NC or si-APOBEC3B (OBiO Technology) were first prepared and then used to transfect KYSE30/DDP cells.

Techniques: Knockdown, Western Blot, Expressing, Immunofluorescence